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A possible explanation as to why the clinical trials of antioxidants might
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A B S T R A C T
Oxidised low density lipoprotein (LDL) was considered to be important in the pathogenesis of atherosclerosis,
but the large clinical trials of antioxidants, including the ﬁrst one using probucol (the PQRST Trial), failed to
show beneﬁt and have cast doubt on the importance of oxidised LDL. We have shown previously that LDL
oxidation can be catalysed by iron in the lysosomes of macrophages. The aim of this study was therefore to
investigate the eﬀectiveness of antioxidants in preventing LDL oxidation at lysosomal pH and also establish the
possible mechanism of oxidation. Probucol did not eﬀectively inhibit the oxidation of LDL at lysosomal pH, as
measured by conjugated dienes or oxidised cholesteryl esters or tryptophan residues in isolated LDL or by ceroid
formation in the lysosomes of macrophage-like cells, in marked contrast to its highly eﬀective inhibition of LDL
oxidation at pH 7.4. LDL oxidation at lysosomal pH was inhibited very eﬀectively for long periods by N,N'-
diphenyl-1,4-phenylenediamine, which is more hydrophobic than probucol and has been shown by others to
inhibit atherosclerosis in rabbits, and by cysteamine, which is a hydrophilic antioxidant that accumulates in
lysosomes. Iron-induced LDL oxidation might be due to the formation of the superoxide radical, which proto-
nates at lysosomal pH to form the much more reactive, hydrophobic hydroperoxyl radical, which can enter LDL
and reach its core. Probucol resides mainly in the surface monolayer of LDL and would not eﬀectively scavenge
hydroperoxyl radicals in the core of LDL. This might explain why probucol failed to protect against athero-
sclerosis in various clinical trials. The oxidised LDL hypothesis of atherosclerosis now needs to be re-evaluated
using diﬀerent and more eﬀective antioxidants that protect against the lysosomal oxidation of LDL.
1. Introduction
Oxidation of low density lipoprotein (LDL) was widely believed to
be a critical step in the pathogenesis of atherosclerosis, the underlying
cause of myocardial infarctions and thrombotic strokes (Steinberg and
Witztum, 2010). The oxidised LDL hypothesis proposes that cells in the
arterial wall oxidise LDL in the extracellular space and then take it up
rapidly, leading to the formation of the foam cells characteristic of
atherosclerosis (Steinberg and Witztum, 2010). Two key problems with
this conventional view are that the oxidation is inhibited by low con-
centrations of interstitial ﬂuid (or serum) (Dabbagh and Frei, 1995),
and that large clinical trials have shown no protection by antioxidants
against cardiovascular disease (Steinberg and Witztum, 2002). To ad-
dress the shortcomings in the conventional LDL oxidation theory, we
proposed that nonoxidatively modiﬁed LDL is rapidly endocytosed by
macrophages and then oxidised within lysosomes (Wen and Leake,
2007). We showed that 7 days after taking up mechanically-aggregated
(vortexed) LDL, mouse J774 cells (a macrophage-like cell line) and
human monocyte-derived macrophages (HMDM) generated ceroid (an
advanced lipid oxidation product present in human atherosclerotic le-
sions) in their lysosomes (Wen and Leake, 2007). Furthermore, there
was an increased production of oxysterols (e.g. 7-ketocholesterol) in the
J774 cells when incubated with nonoxidized acetylated LDL which is
rapidly endocytosed by macrophages, and then incubated in the ab-
sence of extracellular lipoproteins. Chloroquine, a weak base that
concentrates in lysosomes and increases their pH, inhibited the oxida-
tion of LDL, suggesting that the oxidation takes place at acidic pH. It
was further shown that the oxidation in lysosomes is mediated by iron
which is highly eﬀective in oxidising LDL at pH 4.5, the approximate
pH of lysosomes, but very poor at doing so at pH 7.4 in a simple buﬀer
(Satchell and Leake, 2012; Wen and Leake, 2007).
Iron is a transition metal capable of redox cycling between the
oxidation states of Fe2+ and Fe3+. Whether iron in lysosomes exists in
ferric or ferrous state has been a matter of discussion, (Collins et al.,
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1991) and both might be present (Meguro et al., 2005), but because of
the reducing environment within lysosomes the ferrous oxidation state
of iron is likely to be favoured (Terman and Kurz, 2013). Various the-
ories have been proposed for the mechanism of LDL oxidation by iron.
Some suggest that iron may be able to catalyse the oxidation of LDL by
the production of hydroxyl radicals from hydrogen peroxide (Halliwell
and Gutteridge, 1986), while others believe that superoxide ion is re-
quired for the initiation of LDL oxidation (Lynch and Frei, 1993). It is
also believed that iron may be able to initiate the oxidation of LDL by
reacting with pre-existing lipid hydroperoxides (LOOH) in LDL particles
(Esterbauer et al., 1990).
These mechanisms are based on reactions occurring at physiological
pH (Lynch and Frei, 1993), at which iron is practically insoluble and
precipitates unless bound to various molecules, and might not be in-
dicative of the reactions that occur at lysosomal pH. We show here that
antioxidants that have been used to test the oxidised LDL hypothesis do
not inhibit the oxidation of LDL eﬀectively at lysosomal pH and hence
might not be a true test for this hypothesis. We propose another anti-
oxidant, cysteamine, which accumulates in lysosomes and inhibits the
oxidation of LDL eﬀectively at acidic pH, which might provide a better
test for the oxidised LDL hypothesis.
2. Materials and methods
Chemicals and reagents used in this study were purchased from
Sigma-Aldrich, Dorset, UK, or Fisher Scientiﬁc Ltd, Loughborough, UK,
unless otherwise stated. Solutions were prepared using ultrapure water
generated from a Barnstead Nanopure system. Organic solvents were
HPLC or molecular biology grade.
2.1. LDL isolation
Blood was taken from healthy volunteers after overnight fasting
using EDTA (ﬁnal concentration 3mmol/L) as the anticoagulant. LDL
(1.019–1.063 g/mL) was isolated from the plasma by sequential density
ultracentrifugation at 4 °C, as described previously (Wilkins and Leake,
1994). LDL was stored in the presence of 100 μmol/L EDTA in the dark
at 4 °C and used within 1 month.
2.2. Aggregation of LDL with sphingomyelinase
LDL was aggregated by incubating native LDL (2mg protein/mL)
with sphingomyelinase (Bacillus cereus, catalogue number S9396-
25UN, Sigma) at 10mU/mL (Walters and Wrenn, 2010) until the at-
tenuance (absorbance plus light scattering) at 680 nm increased from
about 0.0017–0.027. Sphingomyelinase-aggregated LDL (SMase-LDL)
was dialysed against a phosphate buﬀer containing EDTA and sterilised
by membrane ﬁltration (0.45 μm).
2.3. Measurement of conjugated dienes
LDL (50 μg LDL protein/ml) was oxidised with freshly dissolved
FeSO4 (5 μmol/L) or FeCl3 (5 μmol/L) at 37 °C in a NaCl/sodium acetate
buﬀer (NaCl 150mmol/L, sodium acetate 10mmol/L; pH 4.5) in
capped quartz cuvettes and conjugated dienes were monitored in the
presence or absence of antioxidants using a method based on that of
Esterbauer et al. (Esterbauer et al., 1989). The change in attenuance at
234 nm was measured at 37 °C against reference cuvettes containing all
the components except LDL. Measurements were taken at one minute
intervals in a Lambda-2 6-cell or a Lambda Bio 40 8-cell spectro-
photometer with UV Winlab software. The attenuance at time zero was
subtracted from all values, and the time taken to reach an attenuance of
0.1 was used as a reference since this corresponds to the rapid oxidation
phase (Satchell and Leake, 2012).
2.4. Loss of LDL-tryptophan ﬂuorescence measurement
The decrease in lipoprotein bound tryptophan ﬂuorescence was
measured on a Cary Eclipse ﬂuorescence spectrophotometer using the
time-drive method at an emission wavelength of 331 nm, with excita-
tion set at 282 nm (Giessauf et al., 1995). The emission and excitation
slits were set at 10 nm to obtain optimal ﬂuorescence output. LDL
(50 μg LDL protein/ml) was oxidised by freshly dissolved FeSO4
(5 μmol/L) at 37 °C in the NaCl/sodium acetate buﬀer, pH 4.5 in capped
quartz cuvettes and the tryptophan ﬂuorescence was measured every
10min.
2.5. Monitoring of Fe2+ levels using bathophenanthrolinedisulfonic acid
The ferrous iron chelator bathophenanthrolinedisulfonic acid (BP)
was used to measure ferrous iron concentrations. BP forms a red color
complex with Fe (II) with a molar absorption coeﬃcient of
22,140 Lmol−1 cm−1 at 535 nm (Pieroni et al., 2001). LDL (50 μg
protein/ml) was oxidised with freshly prepared FeSO4 (5 μmol/L) in the
NaCl/sodium acetate buﬀer in polypropylene tubes in a water bath at
37 °C. Samples of 1mL were taken at diﬀerent time points into new
tubes, 30 μL of BP (10mmol/L) was added to them and absorbance was
measured immediately at 535 nm with a spectrophotometer.
2.6. HPLC analysis
Lipids were extracted from oxidised LDL for HPLC analysis using
methanol and hexane (Kritharides et al., 1993; Satchell and Leake,
2012). The upper hexane layer was collected and evaporated at am-
bient temperature in a SpeedVac Concentrator System (ThermoFisher),
the residue was dissolved in the relevant mobile phase before injection
into the HPLC. Lipid species were separated by reverse phase HPLC in a
Waters C18 column (250mm×4.6mm, 5 μm particle size, 5 μm guard
column) with a Agilent 1100 HPLC system. Cholesteryl esters were
detected at 210 nm using an acetonitrile/2-propanol/water mobile
phase (44/54/2, by volume) and a ﬂow rate of 1.2 mL/min. Cholesteryl
linoleate hydroperoxide and 7-ketocholesterol were detected at 234 nm
using an acetonitrile/2-propanol/water mobile phase (50/48.8/1.2, by
volume) and a ﬂow rate of 1mL/min. The identities of the peaks were
conﬁrmed by mass spectrometry (data not shown), and the lipids were
quantiﬁed using commercially available standards.
2.7. Measurement of lipid hydroperoxides
Lipid hydroperoxides (LOOH) were measured using a method
adapted from that described by el-Saadani et al. (1989) Standard con-
centrations of H2O2 were made up using pure water. Samples and
standards (250 μL) were added to assay tubes in triplicate and 1mL of
color reagent (0.2 mol/L potassium phosphate, 0.12mol/L potassium
iodide, 0.15mmol/L sodium azide, polyethyleneglycol mono[p-
(1,1′,3,3′-tetramethyl-butyl)-phenyl]ether (2 g/L), alkylbenzyldi-
methylammonium chloride (0.1 g/L), ammonium molybdate (10 μmol/
L); pH 6.0–6.2) was added to each tube. After leaving the tubes in the
dark for 1 h, the absorbance at 365 nm was measured. The levels of
lipid hydroperoxides were also conﬁrmed by HPLC method as described
above (Fig. S1).
2.8. Cell culture
THP-1 cells were purchased from the European Collection of Cell
Cultures (Salisbury, UK), and cultured in RPMI 1640 containing L-
glutamine to which was added penicillin (50 IU/mL), streptomycin
(50 μg/mL) and amphotericin B (0.95 μg/mL). THP-1cells were diﬀer-
entiated into macrophages on 18× 18mm glass coverslips in 6-well
tissue culture plates using 25 nM phorbol 12-myristate 13-acetate
(25 nmol/L) for 72 h. The cells were then washed three times with PBS
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and allowed to rest for 24 h before treatment with LDL. At the end of
24 h the macrophages were incubated in medium containing either
SMase-LDL or native LDL at 200 μg protein/mL, or without LDL, for
24 h. The medium was washed oﬀ 3 times with warm PBS and the in-
cubation was continued for 7 days with the above medium but con-
taining 10% (v/v) lipoprotein-deﬁcient fetal calf serum (LPDS), instead
of fetal calf serum. LPDS was prepared by ultracentrifugation at 115
000g and 4 °C for 48 h at a density of 1.25 g/mL. The medium was
changed every 2 days. To study eﬀects of antioxidants, probucol
(freshly dissolved in ethanol) and cysteamine (freshly dissolved in PBS),
were added to the cells every day after the LDL had been washed oﬀ. To
demonstrate ceroid, cells on coverslips were ﬁxed with 4% (w/v) par-
aformaldehyde in PBS, treated with ethanol and xylene for 5min each
to remove ‘soluble lipids’ and stained with Oil Red O (0.5%, w/v) (Wen
and Leake, 2007; Wen et al., 2014). Staining was detected using a
transmitted-light microscope equipped with a digital camera (Axioskop
2, Carl Zeiss Ltd). It was quantiﬁed with ImageJ 1.46 (National Institute
of Mental Health, Bethesda, Maryland, USA) by calculating the average
integrated density in ﬁve randomly positioned digital images con-
taining a total of at least 100 cells in each slide.
3. Statistical analysis
Data are presented as the mean ± SEM of at least 3 independent
experiments. Comparisons were made using either a paired student t
test or one-way ANOVA with a Dunnett’s post hoc test or two-way
ANOVA with a Bonferroni posthoc test, as speciﬁed. Diﬀerences were
considered signiﬁcant at P < 0.05.
4. Results
4.1. LDL oxidation with ferrous and ferric iron
Under lysosomal conditions most of the catalytically active iron
present would be expected to be in the ferrous state (Terman and Kurz,
2013), although ferric iron has also been found to be present. (Meguro
et al., 2005) The oxidation of LDL by copper at pH 7.4 is increased by
the presence of pre-existing lipid hydroperoxides (Frei and Gaziano,
1993) and hence LDL which has little or no detectable pre-existing
hydroperoxides should resist oxidation catalysed by iron. There were no
lipid hydroperoxides detected by a tri-iodide assay or by HPLC (Fig. S1)
in any of the batches of freshly isolated LDL. The same LDL was oxi-
dised by ferrous or ferric iron, by measuring conjugated diene forma-
tion and also the loss of LDL-tryptophan ﬂuorescence. It has been
shown that tryptophan residues of apoB-100 are modiﬁed in the early
stages of LDL oxidation by copper ions at pH 7.4 (Giessauf et al., 1995;
Giessauf et al., 1996). Both ferrous and ferric iron were able to induce
the oxidation of fresh LDL at pH 4.5, even though no pre-existing lipid
hydroperoxides were detected. As expected (Satchell and Leake, 2012),
LDL oxidation was signiﬁcantly slower with ferric than ferrous iron.
The expected lag, rapid oxidation, slow oxidation, aggregation and
sedimentation phases were observed at 234 nm (Satchell and Leake,
2012) (Fig. 1A). The loss of tryptophan ﬂuorescence was gradual with
ferric iron, but there was an initial rapid phase followed by a slower
phase with ferrous iron (Fig. 1C). These results suggest that iron is able
to catalyse the oxidation of LDL at pH 4.5 when few if any pre-existing
hydroperoxides are present. Also ferrous iron promotes LDL oxidation
faster than ferric ion and therefore might be a major species involved in
the oxidation of LDL in lysosomes.
4.2. Ferrous iron is consumed during the rapid oxidation phase
As ferrous iron might be the main iron species in lysosomes, we
monitored the concentration of ferrous iron during LDL oxidation, using
the ferrous iron chelator bathophenanthrolinedisulfonic acid (BP).
Samples of oxidising LDL were taken at various times and added to BP
and the absorbance measured immediately, to avoid any artefacts re-
sulting from BP being present during LDL oxidation. Almost all of the
ferrous iron was consumed during the ﬁrst 120min (Fig. 1E). This
corresponds to the rapid LDL oxidation phase seen in the conjugated
diene and LDL-tryptophan ﬂuorescence measurements (Fig. 1A and C).
This suggests that the initial rapid oxidation phase of LDL is due to
ferrous ion, which is probably oxidised to the ferric state, followed by
the slow oxidation phase of LDL in the presence of mainly ferric iron.
Fe2++X→ Fe3++X−
4.3. Eﬀect of hydroperoxide enrichment on LDL oxidation
It is believed that transition metal ions like copper and iron at pH
7.4 can initiate lipid peroxidation by breaking down pre-existing lipid
hydroperoxides (Frei and Gaziano, 1993). Therefore, we wanted to
conﬁrm if the same mechanism is true under lysosomal conditions. We
have shown before that adding 13(S)-hydroperoxyoctadeca-9Z,11E-
dienoic acid (HPODE) to LDL increases the rate of LDL oxidation by
copper ions at pH 7.4. (Patterson et al., 2003) As mentioned above, we
used freshly isolated LDL in our experiments and checked for the pre-
sence of pre-existing lipid hydroperoxides by a tri-iodide assay for total
hydroperoxides and by HPLC (Fig. S1) for cholesteryl linoleate hydro-
peroxide and found negligible levels. In order to study the eﬀect of pre-
existing hydroperoxides on LDL oxidation, fresh LDL was spiked with
lipid hydroperoxides in the form of HPODE (30 and 60 nmol/mg LDL
protein, about 4% and 8%, respectively, of the maximum content of
lipid hydroperoxides in highly oxLDL) (Patterson et al., 2003) prior to
oxidation with iron. Native LDL or lipid hydroperoxide-rich native LDL
(50 μg protein/ml) was oxidised in NaCl/sodium acetate buﬀer (pH 4.5)
at 37 °C with FeSO4. Surprisingly, addition of lipid hydroperoxide
(30 nmol/mg LDL protein) to fresh LDL did not increase its oxidation
with ferrous iron (Fig. 2A and B). Unexpectedly it was seen that after
about 400min oxidation slowed down in LDL spiked with 60 nmol
HPODE/mg protein (Fig. 2A). HPODE also had no eﬀect on the loss of
tryptophan ﬂuorescence with ferrous iron (Fig. 2C and D). These results
indicate that pre-existing lipid hydroperoxides are not involved in in-
itiating the iron-catalysed oxidation of LDL at pH 4.5.
4.4. Oxidation of LDL catalysed by iron in presence of probucol
To further conﬁrm that lipid hydroperoxides are not involved in
initiating LDL oxidation, we used the chain breaking antioxidant pro-
bucol (structure shown in Fig. 3E). Probucol exerts its antioxidant ac-
tivity by donating an electron or a hydrogen atom from one of its
phenolic groups to a lipid radical (Jackson et al., 1991), thus inhibiting
lipid peroxidation. Interestingly, probucol (2 μM) showed no initial
antioxidant eﬀect on LDL lipid oxidation induced by ferrous iron at pH
4.5 but it did slow down the oxidation after about 100min (Fig. 3A and
B). Probucol (2 μM) also did not eﬀectively protect against the initial
loss of tryptophan ﬂuorescence during oxidation of LDL catalysed by
ferrous iron at pH 4.5 (Fig. 3C and D).
4.5. HPLC analysis of LDL oxidation
Probucol has been shown to concentrate in the phospholipid
monolayer surrounding the hydrophobic lipid core of LDL (Bard et al.,
1994) and therefore the initial oxidation of LDL seen in the presence of
probucol suggests that the initial oxidation might be oxidation in the
LDL core. We therefore investigated this by using reverse phase HPLC in
comparison with another antioxidant N,N'-diphenyl-1,4-phenylenedia-
mine (DPPD) (structure shown in Fig. 4E) which has been shown to
protect against atherosclerosis in animals (Sparrow et al., 1992). DPPD
is a strong antioxidant which is capable of donating an electron or a
hydrogen atom from each of its secondary amine groups and prevents
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lipid peroxidation by scavenging LOO% (Takahashi et al., 1989). DPPD
has polar surface area of 24.1 Å2 (PubChem) which is much lower than
that of probucol which has a polar surface area of 91.1 Ǻ2 (PubChem)
and hence DPPD would be expected to concentrate more in the hy-
drophobic core of LDL than does probucol. DPPD completely inhibited
cholesteryl linoleate hydroperoxide (CLOOH) formation by iron at pH
4.5, whereas probucol had no inhibitory eﬀect (Fig. 4A). DPPD com-
pletely protected against the loss of cholesteryl linoleate and cholesteryl
arachidonate, whereas probucol had no eﬀect (Fig. 4B and C) (a re-
presentative HPLC chromatogram is shown in Fig. S3). Furthermore,
Fig. 1. Oxidation of LDL catalysed by FeSO4 and FeCl3 at pH 4.5. LDL (50 μg protein/ml) in NaCl/sodium acetate buﬀer (pH 4.5) was incubated with either FeSO4 or FeCl3 (5 μmol/L) at
37 °C in quartz cuvettes. LDL oxidation was monitored by measuring the change in attenuance at 234 nm against appropriate reference cuvettes (A). Time taken to reach an attenuance
increase of 0.1 is shown (B). Tryptophan ﬂuorescence was measured every 10min at an excitation wavelength of 282 nm and emission wavelength 331 nm in a spectroﬂuorometer (C).
The decrease in ﬂuorescence after 150min is shown (D). Decrease of Fe2+ concentration during LDL oxidation by FeSO4 (E). These are representative examples of at least three
independent experiments (A and C). * indicates p < 0.05; paired t-test (B and D).
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DPPD prevented conjugated diene formation during oxidation with iron
(Fig. 4D). Probucol has limited access to the core so it is unable to
prevent the oxidation of the cholesteryl esters, whereas DPPD gains
access to the core of LDL and is able to completely inhibit its oxidation.
4.6. Lysosomal ceroid formation
To conﬁrm the above ﬁndings of probucol’s failure as an antioxidant
for the initial oxidation of LDL at lysosomal pH, we measured ceroid in
the lysosomes of cultured macrophages. Ceroid is a polymerised pro-
duct of lipid and protein oxidation found within foam cells in human
atherosclerotic lesions (Mitchinson et al., 1985). As mentioned above,
we have previously shown that mechanically aggregated LDL is rapidly
taken up by human macrophages and oxidised in lysosomes generating
ceroid (Wen and Leake, 2007). We have also shown that LDL ag-
gregated by sphingomyelinase is internalised by macrophages and
oxidised in lysosomes (Wen et al., 2014). Cysteamine (2-aminoetha-
nethiol) (structure shown in Fig. 6E) is an antioxidant, which con-
centrates in lysosomes by several orders of magnitude, and is used in
the treatment of a rare lysosomal storage disorder called cystinosis
(Brodin-Sartorius et al., 2012). THP-1 macrophages were treated with
native LDL or SMase-LDL (200 μg protein/ml) or without LDL for 24 h
and were washed and incubated for 7 days in lipoprotein-deﬁcient
medium with or without the antioxidants, probucol (10 μmol/L) and
cysteamine (10 μmol/L). The cells were then stained for ceroid after
other lipids had been removed by organic solvents. Ceroid was clearly
visible in the form of Oil Red O stained, irregularly shaped granules in
cells treated with SMase-LDL (Fig. 5C ) (Mitchinson, 1982). Little ceroid
was present in cells that had been incubated without LDL (Fig. 5A), but
was increased in cells incubated with native LDL (p < 0.05) (Fig. 5B).
There was no signiﬁcant decrease in the ceroid development in cells
incubated with probucol (Fig. 5D), but cells which were treated with
cysteamine (Fig. 5E) showed a signiﬁcant reduction in ceroid forma-
tion. These results show that lysosomal oxidation of LDL is not pre-
vented by probucol but can be inhibited by the lysosomotropic drug
cysteamine.
4.7. Eﬀect of cysteamine on LDL oxidation catalysed by iron at lysosomal
pH
As cysteamine inhibited ceroid formation, we investigated the eﬀect
of cysteamine on LDL oxidation catalysed by iron at pH 4.5. Cysteamine
showed a concentration-dependent inhibition of LDL oxidation cata-
lysed by iron with 25 μmol/L preventing oxidation for about 8 h and
250 μmol/L for over 30 h (Fig. 6A and B). The lower concentration was
chosen to conduct further experiments. Cysteamine (25 μmol/L) con-
centration decreased the oxidation of tryptophan residues of apoB-100
by iron for about ﬁrst 8 h (Fig. 6C and D). Furthermore, cysteamine
completely prevented the loss of cholesteryl arachidonate (Fig. 7A) and
cholesteryl linoleate (Fig. 7B) for 6 h and also prevented the formation
of cholesteryl linoleate hydroperoxide (Fig. 7C) and 7-ketocholsterol
(Fig. 7D) for 6 h. These results indicate that cysteamine is able to pre-
vent the oxidation of the hydrophobic cholesteryl ester core of LDL and
of nonesteriﬁed cholesterol, which is located mainly in the surface
Fig. 2. Eﬀect of HPODE on LDL oxidation catalysed by 5 μM FeSO4 at pH 4.5. Native LDL and HPODE-rich native LDL (30 or 60 nmol/mg LDL protein) were incubated with 5 μM FeSO4 at
pH 4.5 in NaCl/sodium acetate buﬀer (pH 4.5) at 37 °C in quartz cuvettes. Addition of lipid hydroperoxide did not increase the rate of LDL oxidation measured at 234 nm (A). There was
no signiﬁcant diﬀerence in the times the samples took to reach an attenuance of 0.1 (B). Addition of HPODE had no eﬀect on the loss of LDL-tryptophan ﬂuorescence during LDL oxidation
(C). The decrease in tryptophan ﬂuorescence at 150min in the absence or presence of HPODE is shown (D). These are representative examples of at least three independent experiments.
(*** indicates p < 0.001 compared to the control without iron).
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monolayer of LDL (Lund-Katz and Phillips, 1986) as well as the oxi-
dation of tryptophan residues in apoB-100.
5. Discussion
We previously showed that nonoxidatively modiﬁed LDL is en-
docytosed by macrophages and oxidised by iron in their lysosomes
(Wen and Leake, 2007). Iron levels are increased by an order of mag-
nitude in human and animal atherosclerotic lesions (Sullivan, 2009).
Iron is highly eﬀective in oxidising LDL at pH 4.5, the approximate pH
of lysosomes, but very poor at doing so at pH 7.4 in a simple buﬀer
(Wen and Leake, 2007). Animal studies have shown a positive corre-
lation between iron-deposition within plaques and the severity of
atherosclerosis (Lee et al., 1999; Yuan et al., 1996). Low molecular
Fig. 3. Eﬀect of probucol on LDL oxidation catalysed by iron at pH 4.5. LDL (50 μg protein/ml) was incubated with FeSO4 in the presence or absence of 2 μM probucol at pH 4.5 in NaCl/
sodium acetate buﬀer at 37 °C in quartz cuvettes; Oxidation was monitored by measuring the change in attenuance at 234 nm against appropriate reference cuvettes (A). The time
required for the attenuance to reach 0.1 was not signiﬁcantly increased by probucol (B). Probucol was also unable to eﬀectively protect the initial loss of LDL-tryptophan ﬂuorescence
during incubation with iron at pH 4.5 (C). After 80min of LDL oxidation the ﬂuorescence intensity decrease was not signiﬁcantly diﬀerent (P > 0.05) from that in the presence of
probucol (D). Structure of probucol (E). These are representative examples of at least three independent experiments. Mean ± SEM, paired t-test.
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weight, probably redox-active iron has been shown to be present in
lysosomes of macrophage foam cells in human atherosclerotic lesions,
probably because of the degradation of ferritin, the autophagy of iron-
containing organelles or the phagocytosis of erythrocytes (Kurz et al.,
2008). Further to this, L-ferritin levels are increased in coronary arteries
from patients with coronary artery disease, indicating that iron accu-
mulates in atherosclerotic plaques (You et al., 2003). The epidemiology
of iron status and coronary heart disease is inconsistent (Sempos,
2002). This might be because measuring iron in plasma is not a good
measure of iron inside macrophages. For instance, hepcidin is increased
by inﬂammation and decreases iron in plasma but increases it in mac-
rophages (Sullivan, 2009).
It has been proposed that transition metals may be able to initiate
the oxidation of LDL by reacting with pre-existing lipid hydroperoxides
in the LDL particles (Frei and Gaziano, 1993) and ferrous iron is be-
lieved to react faster with lipid hydroperoxides than does ferric iron
(Esterbauer et al., 1992).
Fe2++LOOH→ Fe3++LO%+OH− (fast)
Fe3++LOOH→ Fe2++LOO%+H+ (slow)
The above reactions have been proposed on the basis of rate con-
stants for the analogous reactions of Fe2+ and Fe3+ with H2O2 and not
the actual lipid hydroperoxides (Minotti and Aust, 1992). In addition,
the rate of these reactions is dependent on pH and ferric iron is in-
soluble at pH 7.4 and precipitates (Tachiev et al., 2000).
The current study shows that the initial addition of a lipid hydro-
peroxide (13-HPODE) does not increase the rate of LDL oxidation with
iron at pH 4.5. In fact, addition of a higher amount of 13-HPODE de-
layed the later stage of oxidation of LDL, maybe because it was con-
verting Fe2+ to Fe3+, which is less eﬀective in oxidising LDL (Fig. 1A).
It has previously been shown that the rate of oxidation of LDL by copper
Fig. 4. HPLC analysis of LDL oxidation catalysed by FeSO4 at pH 4.5. LDL (50 μg protein/mL) in NaCl/sodium acetate buﬀer at pH 4.5 was incubated with 5 μM FeSO4 at 37 °C in the
presence or absence of probucol (2 μmol/L) or DPPD (2 μmol/L) and samples were taken every 30min to be analysed by reverse-phase HPLC for cholesterol linoleate hydroperoxide
(CLOOH) (A) at 234 nm and cholesteryl linoleate (B) and cholesteryl arachidonate (C) at 210 nm. Measure of conjugated diene formation in presence of DPPD (D). Structure of DPPD (E).
The statistics shown are two way ANOVA followed by Bonferroni post-test (p < 0.0001) compared to the control. Graphs represent the mean ± the SEM of at least three independent
experiments.
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at pH 7.4 is increased considerably by HPODE (Patterson et al., 2003).
Therefore, the present data suggest that the initial oxidation of LDL
induced by iron at lysosomal pH is independent of the presence of lipid
hydroperoxides.
The concentration of Fe2+ decreased rapidly to low levels during
the ﬁrst 60min of LDL oxidation at pH 4.5 (Fig. 1E), which corresponds
almost exactly to the rapid phase of LDL oxidation (Fig. 1A). Our pre-
vious work has also shown that adding higher concentrations of Fe2+
shortened the lag phase and increased the rates of the rapid, slow, and
aggregation phases of LDL oxidation, whereas adding higher con-
centrations of Fe3+ had little eﬀect (Satchell and Leake, 2012). The
formation of conjugated dienes (Fig. 1A) and decrease in tryptophan
ﬂuorescence (Fig. 1C) both occurred faster with Fe2+ than with Fe3+,
again suggesting the important role of ferrous compared to ferric iron.
Probucol eﬃciently inhibits LDL oxidation by cells or copper at
physiological pH (Parthasarathy et al., 1986), by scavenging lipid
Fig. 5. Inhibition of ceroid formation in THP-1 macrophages. THP-1 macrophage-like cells were incubated with native or SMase-LDL (200 μg protein/mL) for 24 h. They were then
incubated for a further 7 days in the absence of lipoproteins in RPMI with 10% (v/v) LPDS in the presence or absence of probucol or cysteamine. A shows cells incubated without LDL or
antioxidants, B shows cells incubated with native LDL only, C shows cells incubated with SMase-LDL but without antioxidants, D shows cells incubated with SMase-LDL and then probucol
(10 μmol/L) and E shows cells incubated with SMase-LDL and then cysteamine (10 μmol/L). The ceroid levels in the cells were quantiﬁed using ImageJ as mean integrated density of at
least 100 cells and expressed as percent decrease of cells treated with only SMase-LDL (F). Mean ± SEM of 3 independent experiments. * p < 0.05, ** p < 0.01, compared to SMase-
LDL, ANOVA and Dunnett’s test.
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radicals (L%, LO%, LOO%) and hence inhibiting the lipid peroxidation
chain reaction. The initial oxidation of LDL catalysed by iron at pH 4.5,
however, was not eﬀectively inhibited by probucol measured by either
conjugated dienes (Fig. 3A, B) or loss of tryptophan ﬂuorescence
(Fig. 3C, D). In support of this, the oxidation of the cholesteryl esters in
the core of LDL was not inhibited by probucol, as measured in terms of
the formation of cholesteryl linoleate hydroperoxide or loss of choles-
teryl linoleate or arachidonate (Fig. 5). In contrast, cholesteryl ester
oxidation was inhibited entirely by the very hydrophobic antioxidant
DPPD. Probucol inhibited the oxidation of LDL after about 100min and
this might be due to an antioxidant eﬀect on the phospholipid mono-
layer of LDL. This suggests that the oxidation of LDL catalysed by iron at
pH 4.5 starts in the hydrophobic core (containing cholesteryl esters and
triacylglycerols), where DPPD would be expected to accumulate, rather
than in the surface monolayer (containing mainly phospholipids and
nonesteriﬁed cholesterol) where probucol mainly resides (Bard et al.,
1994),
Tryptophan loss is one of the most signiﬁcant oxidative changes in
oxidised proteins due to the high susceptibility of this amino acid to
reactive oxygen species (Ronsein et al., 2011). ApoB-100 of LDL con-
tains 37 tryptophan residues and these have been proposed to be re-
sponsible for the initiation of LDL oxidation by copper ions (Giessauf
et al., 1995). We found that there was loss of LDL-tryptophan ﬂuores-
cence during iron-catalysed oxidation at pH 4.5, which was unaﬀected
by the addition of hydroperoxides and was not prevented by probucol.
Although, DPPD greatly prevented the formation of conjugated dienes
(Fig. 5D), we could not investigate the eﬀect of DPPD on the loss of
tryptophan ﬂuorescence because DPPD absorbs at 331 nm (Linschitz
et al., 1967) and quenched the ﬂuorescence of tryptophan (Fig. S2). It
was also noted that the loss of LDL-tryptophan ﬂuorescence occurs
faster when LDL is oxidised with Fe2+ than Fe3+ (Fig. 1C, D). Lynch
and Frei (1993) suggested that reduction of Fe3+ to Fe2+ in the pre-
sence of an exogenous reductant such as superoxide (O2%−) is essential
for iron-catalysed LDL oxidation at pH 7.4.
Fig. 6. Eﬀect of cysteamine on LDL oxidation catalysed by iron at pH 4.5. LDL (50 μg protein/ml) was oxidised in the presence or absence of cysteamine by FeSO4 (5 μmol/L) at pH 4.5 in
NaCl/sodium acetate buﬀer at 37 °C. Oxidation was monitored by measuring the change in attenuance at 234 nm against appropriate reference cuvettes (A). The time required for the
attenuance to reach 0.1 was signiﬁcantly increased by cysteamine (25 μmol/L) (p < 0.001) (B) mean ± SEM, paired t-test, ***p < 0.001. Cysteamine (25 μmol/L) prevented the initial
loss of LDL- tryptophan ﬂuorescence on oxidation with iron (C). After 150min of LDL oxidation with iron, the ﬂuorescence intensity decrease was signiﬁcantly less (p < 0.001) in the
presence of cysteamine (D), mean ± SEM, paired t-test. (E) shows the structure of cysteamine.
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The concentration of Fe2+ falls rapidly when LDL is oxidised at pH
4.5 (Fig. 1E) and is converted presumably to Fe3+ generating super-
oxide radicals (Morgan and Lahav, 2007).
Fe2++O2→ Fe3++O2%−
The superoxide radical undergoes protonation at pH 4.5 to form its
conjugate acid, hydroperoxyl radical, which is highly reactive (De Grey,
2002).
O2%−+H+↔HO2% (pKa 4.8)
At pH 7.4, only about 0.25% of superoxide would be present as
hydroperoxyl radical, whereas at pH 4.5 about 67% of it would be
present as the hydroperoxyl radical. Hydroperoxyl radical is a much
more potent oxidant than superoxide anion and capable of abstracting a
hydrogen atom from a polyunsaturated fatty acid (De Grey, 2002) as
well as tryptophan (Dubinina et al., 2002) and oxidising LDL (Bedwell
et al., 1989). Superoxide anions are negatively charged and hydrophilic
and might not be able to enter the core of LDL or the hydrocarbon chain
region of the surface phospholipid monolayer. Hydroperoxyl radicals,
as well as being more reactive than superoxide anions, are not charged
and would be able to diﬀuse from the aqueous phase into the core of the
LDL particles and abstract hydrogen atoms from the polyunsaturated
fatty acyl groups of cholesteryl esters and triacylglycerols (Bedwell
et al., 1989).
LH+HO2%→ L%+H2O2
TrpH+HO2% → Trp%+H2O2
Lipid radicals and tryptophan radicals would react with oxygen to
form their respective peroxyl radicals. The lipid peroxyl radicals would
then lead to the lipid peroxidation chain reaction.
L%+O2→ LOO%
LOO%+L’→ LOOH+L’%
Trp%+O2→ TrpOO
Antioxidants containing thiol groups are potent nucleophiles and
ready to interact with electrophilic groups of reactive oxygen species
(ROS) (Güngör et al., 2011). Thiols, like cysteamine are capable of
scavenging the superoxide radical in both its anionic (O2%−) and pro-
tonated forms (HO2%) (Cardey et al., 2007).
+ ° → ° +NH -CH -CH -SH HO NH -CH -CH -S H O
cysteamine thiyl radical
2 2 2 2 2 2 2 2 2
Ceroid (lipofuscin) is a ﬁnal product of lipid oxidation that consists
of insoluble polymerized lipid and protein complexes and is found
within foam cells in atherosclerotic lesions (Mitchinson, 1982). Cy-
steamine inhibited lysosomal ceroid formation in human macrophage-
like cells possibly by scavenging the hydroperoxyl radical in the lyso-
somes, whereas probucol had little eﬀect (Fig. 5). Cysteamine was able
to completely prevent lipid peroxidation for long periods of time, as
measured in terms of conjugated dienes, cholesteryl linoleate hydro-
peroxide and 7-ketocholesterol formation and loss of cholesteryl li-
noleate and arachidonate, as well as oxidation of the tryptophan re-
sidues of apoB-100 of LDL (Figs. 6 and 7).
Based on our data, we conclude that the initial oxidation of LDL
catalysed by iron at lysosomal pH is mediated by hydroperoxyl radicals
and is not dependent on pre-existing lipid hydroperoxide levels.
Fig. 7. HPLC analysis of LDL oxidation catalysed by FeSO4 with or without cysteamine. LDL (50 μg protein/ml) was incubated with FeSO4 (5 μmol/L) in the presence or absence of
cysteamine at pH 4.5 in NaCl/sodium acetate buﬀer at 37 °C. Samples were analysed by reverse-phase HPLC for cholesteryl linoleate (A), cholesterol arachidonate (B) and cholesteryl
linoleate hydroperoxide (C) and 7-ketocholestrol (D). The statistics shown are two way ANOVA followed by Bonferroni post-test (*p < 0.05, ***p < 0.001) compared to the control.
Graphs represent the mean ± the SEM of at least three independent experiments.
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Furthermore the oxidation of LDL in the lysosomes of macrophages is
prevented by the lysosomotropic drug cysteamine, which scavenges
hydroperoxyl and superoxide radicals in the aqueous phase (Fig. 8).
Probucol was initially introduced as a cholesterol-lowering drug in
early 1970′s and later it was found to attenuate atherosclerotic lesion
development in most animal models (Carew et al., 1987). However, the
ﬁndings of The Probucol Quantitative Regression Swedish Trial
(PQRST) in 1995 showed that the treatment of hypercholesterolaemic
patients with probucol does not decrease the volume of femoral artery
atherosclerotic lesions (Walldius et al., 1994). Two other clinical stu-
dies, The Aggressive Reduction of Inﬂammation Stop Events (ARISE)
(Tardif et al., 2018) and Probucol Observational Study Illuminating
Therapeutic Impact on Vascular Events (POSITIVE) (Yamashita et al.,
2008), were conducted to assess diﬀerent aspects of the treatment with
probucol or its analog succinobucol, but both failed to demonstrate any
signiﬁcant beneﬁts for the primary endpoints, although there were
some beneﬁcial eﬀects. Our ﬁnding that probucol gives no protection
against oxidation in the cholesteryl ester core of LDL at lysosomal pH
oﬀers an explanation about probucol’s low eﬃcacy in the clinical trials,
if LDL oxidation takes place mainly in the lysosomes of macrophages.
We have previously shown that enrichment of LDL with α-tocopherol
has some pro-oxidant eﬀects in the presence of iron at lysosomal pH
(Satchell and Leake, 2012). There are other possibilities to explain the
low eﬃcacy of these antioxidants in the clinical trials, however, such as
low penetration into atherosclerotic lesions, an inappropriate dose or
that the treatment was started too late.
DPPD inhibited LDL oxidation very eﬀectively in both the core and
monolayer. It is of interest that it protects considerably against ather-
osclerosis in cholesterol-fed rabbits (Sparrow et al., 1992), but it cannot
be used in humans because it is mutagenic. Water-soluble antioxidants
that accumulate in lysosomes, such as cysteamine, that can scavenge
hydroperoxyl radicals in the acidic aqueous phase of lysosomes have
potential to treat atherosclerosis in humans.
In summary, the most eﬀective antioxidants to test the oxidised LDL
hypothesis of atherosclerosis might be lysosomotropic water-soluble
antioxidants or highly hydrophobic antioxidants, which can protect
both the core and monolayer of LDL from oxidation, rather than
moderately hydrophobic antioxidants, such as probucol, which can
only protect the monolayer but not the core of LDL from oxidation.
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